Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells

BACKGROUND: Mesenchymal stem/stromal cells (MSC) accumulate and reside in tumor sites. METHODS: Taking advantage of this feature in anticancer therapy, immortalized murine MSC (iMSC) were genetically altered to produce chemokine (C-C motif) ligand 19 (iMSC/CCL19), which attracts dendritic cells (DC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Iida, Yuichi, Yoshikawa, Rintaro, Murata, Akihiko, Kotani, Hitoshi, Kazuki, Yasuhiro, Oshimura, Mitsuo, Matsuzaki, Yumi, Harada, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368496/
https://www.ncbi.nlm.nih.gov/pubmed/32675195
http://dx.doi.org/10.1136/jitc-2020-000582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368496/
https://www.ncbi.nlm.nih.gov/pubmed/32675195
http://dx.doi.org/10.1136/jitc-2020-000582

Ejemplares similares